Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Update

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,100,000 shares, a decline of 29.9% from the December 15th total of 1,570,000 shares. Based on an average trading volume of 9,060,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.3% of the company’s stock are sold short.

Syros Pharmaceuticals Trading Up 3.4 %

SYRS traded up $0.01 on Friday, hitting $0.21. 339,382 shares of the company’s stock were exchanged, compared to its average volume of 2,484,598. The stock has a fifty day moving average of $0.40 and a two-hundred day moving average of $2.20. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $7.96. The firm has a market cap of $5.69 million, a PE ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the prior year, the business earned ($1.35) EPS. On average, analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Transactions at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SYRS. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the 3rd quarter valued at about $34,000. Acadian Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Finally, Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the last quarter. Institutional investors and hedge funds own 91.47% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SYRS shares. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, StockNews.com began coverage on Syros Pharmaceuticals in a report on Thursday. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.